Discussion

ImmTACs are soluble TCR-based bi-specific reagents suitable for the treatment of several tumour types. These reagents combine picomolar-affinity antigen recognition, with effective immune-activation via an anti-CD3 antibody fragment, to drive potent T cell redirection and cancer cell killing. Unlike monoclonal antibodies, TCRs target MHC-bound peptide antigens derived from endogenously processed proteins, providing a large pool of intracellular antigens from which to select appropriate target molecules. This presentation will focus on pre-clinical data generated for our current lead ImmTAC candidate, IMCgp100 currently in a phase IIa clinical trial for the treatment of malignant melanoma.